123
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Antimicrobial Susceptibility of Ertapenem in Neisseria gonorrhoeae Isolates Collected Within the China Gonococcal Resistance Surveillance Programme (China-GRSP) 2018

ORCID Icon, , ORCID Icon, ORCID Icon, , , , , ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 4183-4189 | Published online: 12 Oct 2021

References

  • Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019;97(8):548P–562P. doi:10.2471/BLT.18.22848631384073
  • Skerlev M, Čulav-košćak I. Gonorrhea: new challenges. Clin Dermatol. 2014;32(2):275–281. doi:10.1016/j.clindermatol.2013.08.01024559563
  • Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1996;349(9069):1868–1873. doi:10.1016/S0140-6736(97)02190-9
  • Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187.
  • Australian Sexual Health Alliance. Australian STI management guidelines for use in primary care; 2019. Available from: http://www.sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea#management. Accessed September 27, 2020.
  • Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections; 2017. Available from: http://publications.gc.ca/collections/collection_2017/aspc-phac/HP40-1-2017-2-eng.pdf. Accessed September 27, 2020.
  • Unemo M, Ross J, Serwin AB, Gomberg M, Cusini M, Jensen JS. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020;956462420949126. doi:10.1177/095646242094912633121366
  • The New Zealand Sexual Health Society. New Zealand guideline for the management of gonorrhoea, 2014, and response to the threat of antimicrobial resistance; 2014. Available from: https://www.nzshs.org/docman/guidelines/best-practice-guidelines/142-new-zealand-guideline-for-the-management-of-gonorrhoea-2014-and-response-to-the-threat-of-antimicrobial-resistance/file. Accessed September 27, 2020.
  • World Health Organization. WHO Guidelines for the Treatment of Neisseria Gonorrhoeae. Geneva: WHO; 2016.
  • National Center for STD Control, Chinese Center for Disease Control and Prevention; Venereology Group, Chinese Society of Dermatology; Subcommittee on Venereology, China Dermatologist Association. Guidelines for diagnosis and treatment of syphilis, gonorrhea and genital Chlamydia trachomatis infection (2020). Chin J Dermatol. 2020;53(3):168–179.
  • Wi T, Lahra MM, Ndowa F, et al. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med. 2017;14(7):e1002344. doi:10.1371/journal.pmed.100234428686231
  • Lefebvre B, Martin I, Demczuk W, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Canada, 2017. Emerg Infect Dis. 2018;24(2):381–383. doi:10.3201/eid2402.171756
  • Lahra MM, Ryder N, Whiley DM. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med. 2014;371(19):1850–1851. doi:10.1056/NEJMc140810925372111
  • Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill. 2018;23(27). doi:10.2807/1560-7917.ES.2018.23.27.1800323.
  • Lewis DA. New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance. Sex Health. 2019;16(5):449–456. doi:10.1071/SH1903431292063
  • Unemo M, Golparian D, Limnios A, et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? Antimicrob Agents Chemother. 2012;56(7):3603–3609. doi:10.1128/AAC.00326-1222547617
  • Eyre DW, Town K, Street T, et al. Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018. Eurosurveillance. 2019;24(10):1900147. doi:10.2807/1560-7917.ES.2019.24.10.1900147.
  • Yin YP, Han Y, Dai XQ, et al. Susceptibility of Neisseria gonorrhoeae to azithromycin and ceftriaxone in China: a retrospective study of national surveillance data from 2013 to 2016. PLoS Med. 2018;15(2):e1002499. doi:10.1371/journal.pmed.100249929408881
  • Zheng XL, Xu WQ, Liu JW, et al. Evaluation of drugs with therapeutic potential for susceptibility of Neisseria gonorrhoeae isolates from 8 provinces in China from 2018. Infect Drug Resist. 2020;13:4475–4486. doi:10.2147/IDR.S27802033364794
  • Unemo M, Golparian D, Sánchez-Busó L, et al. The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. J Antimicrob Chemother. 2016;71(11):3096–3108. doi:10.1093/jac/dkw28827432602
  • Dong Y, Yang Y, Wang Y, Martin I, Demczuk W, Gu W. Shanghai Neisseria gonorrhoeae isolates exhibit resistance to extended-spectrum cephalosporins and clonal distribution. Front Microbiol. 2020;11:580399. doi:10.3389/fmicb.2020.58039933123111
  • Wang H, Wang Y, Yong G, et al. Emergence and genomic characterization of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in Chengdu, China. J Antimicrob Chemother. 2020;75(9):2495–2498. doi:10.1093/jac/dkaa12332363389
  • Bradford PA, Miller AA, O’Donnell J, Mueller JP. Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates. ACS Infect Dis. 2020;6(6):1332–1345. doi:10.1021/acsinfecdis.0c0002132329999
  • Flamm RK, Farrell DJ, Rhomberg PR, Scangarella-Oman NE, Sader HS. Gepotidacin (GSK2140944) in vitro activity against gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2017;61(7):e00468–17. doi:10.1128/AAC.00468-1728483959
  • DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33. doi:10.1016/j.jhealeco.2016.01.01226928437
  • Yang F, Yan J, Zhang J, van der Veen S. Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China. Int J Antimicrob Agents. 2020;55(2):105846. doi:10.1016/j.ijantimicag.2019.11.00331760083